Originally published In Press as doi:10.1074/jbc.M202962200 on April 30, 2002
J. Biol. Chem., Vol. 277, Issue 27, 24306-24314, July 5, 2002
Glucose Regulates Insulin Mitogenic Effect by Modulating SHP-2
Activation and Localization in JAr Cells*
Giuseppe
Bifulco
§,
Costantino
Di Carlo
,
Matilde
Caruso¶,
Francesco
Oriente¶,
Attilio
Di Spiezio
Sardo
,
Pietro
Formisano¶,
Francesco
Beguinot¶, and
Carmine
Nappi
From the
Dipartimento di Ginecologia, Ostetricia e
Fisiopatologia della Riproduzione Umana and the ¶ Dipartimento di
Biologia e Patologia Molecolare e Cellulare "L. Califano,"
Università degli Studi di Napoli "Federico II," 80131 Naples, Italy
Received for publication, March 27, 2002, and in revised form, April 23, 2002
 |
ABSTRACT |
The glucose effect on cell growth has been
investigated in the JAr human choriocarcinoma cells. When JAr cells
were cultured in the presence of 6 mM glucose (LG),
proliferation and thymidine incorporation were induced by serum,
epidermal growth factor, and insulin-like growth factor 1 but
not by insulin. In contrast, at 25 mM glucose (HG),
proliferation and thymidine incorporation were stimulated by insulin,
serum, epidermal growth factor, and insulin-like growth factor 1 to a
comparable extent, whereas basal levels were 25% lower than those in
LG. HG culturing also enhanced insulin-stimulated insulin receptor and
insulin receptor substrate 1 (IRS1) tyrosine phosphorylations while
decreasing basal phosphorylations. These actions of glucose were
accompanied by an increase in cellular tyrosine phosphatase activity.
The activity of SHP-2 in HG-treated JAr cells was 400% of that
measured in LG-treated cells. SHP-2 co-precipitation with IRS1 was also
increased in HG-treated cells. SHP-2 was mainly cytosolic in LG-treated
cells. However, HG culturing largely redistributed SHP-2 to the
internal membrane compartment, where tyrosine-phosphorylated IRS1
predominantly localizes. Further exposure to insulin rescued SHP-2
cytosolic localization, thereby preventing its interaction with IRS1.
Antisense inhibition of SHP-2 reverted the effect of HG on basal and
insulin-stimulated insulin receptor and IRS1 phosphorylation as well as
that on thymidine incorporation. Thus, in JAr cells, glucose modulates
insulin mitogenic action by modulating SHP-2 activity and intracellular localization.
 |
INTRODUCTION |
Glucose controls a variety of cellular functions. Changes in the
extracellular concentrations of glucose may determine either increased
cell proliferation or cell death (1-3). For instance,
-cell
mitogenesis is stimulated by glucose through a protein kinase
C-dependent mechanism (4, 5). In contrast, in human endothelial cells, high glucose concentrations activate c-Jun N-terminal kinase signaling and trigger apoptosis (6). Previous evidence indicates that glucose modulates the transduction pathways of
many growth factors (7-13). However, the mechanisms responsible for
glucose control of growth signaling have not been extensively investigated.
Chronic abnormalities in glucose concentration in the extracellular
fluids may lead to impaired tissue homeostasis (14). High blood glucose
levels in pregnant women with diabetes often causes placenta
hypercellularity, resulting in larger and heavier placentas (15). There
is evidence that placenta growth is regulated by glucose as well as by
growth factors (16-20). In vitro, epidermal growth factor
(EGF),1 insulin-like growth
factor 1 (IGF-1), and transforming growth factor
stimulate
proliferation of cultured human cytotrophoblast cells and their ability
to produce human chorionic gonadotropin and progesterone (21). Insulin
also induces proliferative responses in placenta, likely because of the
activation of the insulin receptor substrate (IRS)/mitogen-activated
protein kinase (MAPK) pathway (20). In several cell types, insulin
signaling is regulated by glucose at different levels (7, 22). But
whether and how glucose affects insulin mitogenic signaling in placenta
is unclear.
In the present work, we have addressed this issue by investigating
glucose regulation of insulin action in the JAr human choriocarcinoma cell line. We show that in this placenta cell model, glucose regulates insulin signaling via the IRS1/MAPK pathway and mitogenesis by modulating the activity and subcellular localization of the SHP-2 tyrosine phosphatase.
 |
EXPERIMENTAL PROCEDURES |
Materials--
JAr and BeWo cell lines were purchased from the
American Type Culture Collection (Manassas, VA). Media and sera for
cell culture were purchased from Sigma. Protein A-Sepharose
beads were from Pierce. Radiochemicals and Western blot and ECL
reagents were from Amersham Biosciences. Monoclonal phosphotyrosine and
monoclonal IRS1 antibodies were from Upstate Biotechnology, Inc. (Lake
Placid, NY), and the mAb3IR antibody was from Oncogene Science
(Manhasset, NY). The phospho-p44/42 MAPK antibody was purchased
from New England Biolabs (Beverly, MA). MAPK, SHP-2, PTP1B, and LAR
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). The
SHP-2 sense and antisense oligonucleotides have been described
previously and characterized (23) and were synthesized by PRIMM s.r.l
(Milan, Italy). LipofectAMINE and Optimem were purchased from
Invitrogen. All of the other reagents were from Sigma.
Cell Culture and Transfection and Cell
Subfractionation--
JAr, BeWo, and 3T3 cells were routinely grown at
37 °C with 95% air, 5% CO2 in DMEM supplemented with
10% fetal bovine serum (FBS). Transient transfection experiments were
performed with the LipofectAMINE method according to the
manufacturer's instructions. Briefly, 50-80% confluent JAr cells
were washed twice with Optimem and incubated for 8 h with 10 µg
of SHP-2 antisense oligonucleotides or with an equal amount of control
oligonucleotides. The medium was replaced with DMEM supplemented with
10% fetal calf serum, and the cells were further incubated for 6 h before being assayed. The cells were incubated in Hepes buffer
containing 12.5 mM Hepes, pH 7.4, 120 mM NaCl,
6 mM KCl, 1.2 mM MgSO4, 1 mM CaCl2, 1 mM Na2HPO4, and 20 mM Hepes,
supplemented with either 6 mM or 25 mM glucose
for 48 h. Insulin (100 nM) was then added in the last 10 min of incubation, where indicated. The cells were washed two times
with Hepes buffer and homogenized in 20 mM Hepes, 250 mM sucrose, 1 mM EDTA, 5 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride, 1 µM leupeptin, pH 7.4. Subcellular fractions were prepared by a modification of the methods of Simpson (24). Briefly, the cells
were washed with ice-cold buffer A (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 255 mM sucrose, 1 mM
phenylmethylsulfonyl fluoride, 10 mM NaF, 100 µM Na3VO4, 1 mM
NaP2O7, 5 µg/ml aprotinin, and 5 µg/ml
leupeptin) and broken in ice-cold buffer A by passing through a
27-gauge needle and centrifuged at 800 × g for 5 min at 4 °C to pellet nuclei. The supernatants were centrifuged at 16,000 × g for 20 min at 4 °C. The pellets were
applied on a 1.12 M sucrose cushion and centrifuged at
212,000 × g for 70 min for preparation of the plasma
membrane fraction. The supernatants were further centrifuged at
212,000 × g for 20 min for preparation of the internal
membrane (pellet) and cytosol (supernatant) fractions (24). The purity
of the subcellullar fractions was assessed by Western blot analysis of
cytochrome c oxidase (internal membrane) and tubulin
(cytosol) and by determination of 5'-nucleotidase activity (plasma
membrane) according to Refs. 25, 26, and 27, respectively.
[3H]Thymidine Incorporation--
For this assay,
the cells were plated in 24-well plates (105 cells/well) in
DMEM supplemented with 10% FBS. After 12 h, the medium was
substituted with glucose-free DMEM supplemented with 0.25% bovine
serum albumin for 16h. The cells were then incubated in the medium
supplemented with 6 mM (LG) or 25 mM (HG)
glucose with or without insulin (100 nM), IGF-1 (100 nM), EGF (100 ng/ml), and FBS (10%) for the indicated
times. In control experiments the cells were incubated in glucose-free
DMEM containing 6 or 25 mM sucrose or fructose. 5 µCi/ml
[3H]thymidine were added, and the incubation was
prolonged for 4 h more. The cells were then lysed in 1 N NaOH, and radioactivity was counted by liquid
scintillation counting.
Cell Proliferation and DNA Fragmentation Assay--
For
proliferation assay, JAr cells were plated in 24-well multiplates
(2 × 104 cells/plate) in DMEM supplemented with 10%
FBS. 12 h later, this medium was replaced with serum-free DMEM
containing 0.25% bovine serum albumin. After an additional 12 h,
the medium was substituted with DMEM containing either 6 or 25 mM glucose and growth factors for the indicated times. For
DNA fragmentation analysis, JAr cells were deprived of serum and
glucose for 12 h and then incubated for 48 h in DMEM
containing 6 or 25 mM glucose in the absence or presence of
100 nM insulin and 25 ng/ml TNF
. The cells (2 × 106) were lysed in 0.5 ml of lysis buffer (10 mM Tris, pH 7.5, 0.6% SDS, 10 mM EDTA). The
RNase solution was added to a concentration of 15 µg/ml, and the cell
lysates were incubated for 20 min at 37 °C. NaCl was then added to 1 M (final concentration) followed by incubation at 4 °C
for 2 h. The samples were centrifuged at 14,000 × g (4C for 30 min), and supernatant DNA was extracted by
phenol-chloroform and ethanol precipitation at
20 °C overnight. Upon centrifugation at 14,000 × g, the DNA pellet was
air dried and dissolved in 20 µl of 10 mM Tris, 10 mM EDTA. Identical amounts of DNA were electrophoresed on
1.5% agarose gels containing 0.5 µg/ml ethidium bromide and
visualized by UV light as described in Ref. 28.
Insulin Receptor Binding and Insulin Degradation--
Insulin
receptor binding was performed by radioreceptor assay as described in
Ref. 29. For this assay, JAr cells were deprived of serum and glucose
for 16 h and then incubated in DMEM supplemented with 6 or 25 mM glucose for 48, 96, or 128 h. The cells were then incubated for 12 h at 4 °C in 1 ml of binding buffer (pH 7.8, 25 mM Tris-HCl, 120 mM NaCl, 1.2 mM
MgSO4, 2.5 mM KCl, 2% bovine serum albumin, 1 mg of Bacitracin) containing 20,000 cpm 125I-insulin.
Nonspecific binding was determined in the presence of 8.5 × 10
5 insulin and was subtracted from the total bound
radioactivity to yield the specific binding. The binding data were
analyzed using the Ligand program for curve fitting and parameter
estimation (30). Insulin degradation was determined by trichloroacetic acid precipitation as described in Ref. 31.
IR and IRS1 Phosphorylation--
For IR phosphorylation studies,
JAr cells were deprived of serum and glucose for 12 h and then
incubated in DMEM supplemented with 6 or 25 mM glucose for
48 h. The cells were then stimulated with 100 nM
insulin for 10 min and solubilized in 1% Triton X-100, 50 mM Hepes, pH 7.5, 150 mM NaCl, 10 µg/ml
aprotinin, 10 µg/ml leupeptin, and 1 mM
phenylmethylsulfonyl fluoride. The insoluble material was separated by
ultracentrifugation at 100,000 × g for 1 h at
4 °C. The supernatant was applied to a wheat germ
agglutinin-Sepharose column pre-equilibrated with buffer containing
0.1% Triton X-100, 50 mM Hepes, pH 7.5, 150 mM
NaCl, and the protease inhibitors described above. The column was
washed using the same buffer, and bound glycoproteins were eluted in
the same buffer containing 0.3 M
N-acetylglucosamine. For IRS1 phosphorylation studies, the cells were lysed in 50 mM Hepes, pH 7.5, 150 mM
NaCl, 10% glycerol, 10 mM EDTA, 10 mM
Na4P2O7, 1 mM
Na3VO4, 10 µg/ml aprotinin, 10 µg/ml
leupeptin, 100 mM NaF, and 1 mM
phenylmethylsulfonyl fluoride (TA buffer) containing 1% Triton X-100.
The cell extracts were then blotted with IR, IRS1, or phosphotyrosine
antibodies or precipitated with IR- and IRS1-specific antibodies
followed by Western blotting with phosphotyrosine antibody as described
in Ref. 32.
MAPK Phosphorylation and PTPase Assay--
JAr cells were
incubated in 6 or 25 mM glucose and stimulated with insulin
as described above. The cells were then lysed in TA buffer supplemented
with 0.1% Triton-X-100 (TAT). The lysates were separated on 12%
SDS-PAGE, transferred on nitrocellulose filter, and then blotted with
phospho-MAPK or MAPK antibodies according to Ref. 33. Alternatively, to
determine protein-tyrosine phosphatase (PTPase) activity, the cells
were incubated with or without 2 mM sodium vanadate in
phosphate-free buffer for 20 min at 37C, according to Ref. 34.
Incubation with 100 µM pervanadate instead of 2 mM vanadate yielded identical results. The cells were lysed
in 0.5% Triton-X-100 and then immunoprecipitated with IR-, IRS1-, and
SHP-2-specific antibodies. The pellets were resuspended in 50 mM Hepes, pH 7.0, and the reactions were initiated by the addition of 20 mM p-nitrophenyl phosphate at
37 °C for 15 min. The reactions were stopped with 1 N
NaOH, and release of p-nitrophenol was
spectrophotometrically quantitated at 410 nm. PTPase
(vanadate-sensitive activity) was expressed as the difference between
the total phosphatase activity (measured in the absence of vanadate)
and the vanadate-resistant activity.
PTPs IRS1 Association--
JAr cells were incubated in 6 or 25 mM glucose and stimulated with insulin as described above.
The cells were then lysed with TAT buffer, and the extracts were
incubated with Sepharose-bound IR or IRS1 antibodies at 4 °C for
3 h. The beads were washed with TA buffer containing 0.1% Triton
X-100, and bound proteins were released by heating at 65 °C for 5 min with SDS sampling buffer (4% SDS, 10% glycerol, 100 mM Tris, pH 6.8, 1 mM EDTA, 10 mM
dithiothreitol, and 8 M urea). The released proteins were
blotted with SHP-2, PTP1B, or LAR antibodies and revealed by ECL and autoradiography.
 |
RESULTS |
Glucose Action on Cell Proliferation in JAr Cells--
We
investigated growth factor effect on DNA synthesis in JAr cells
cultured in the presence of either LG or HG. At 6 mM
glucose, IGF-1 (100 nM), EGF (100 ng/ml), and FBS (10%)
caused a time-dependent increase of thymidine incorporation
in JAr cell nuclei (Fig. 1A). In contrast, insulin (100 nM) had no effect in stimulating
thymidine incorporation. Culturing the cells in HG caused a 25%
decrease in thymidine incorporation as compared with LG
(p < 0.05) (Fig. 1C). However, in HG cells,
insulin increased thymidine incorporation by 350% after 96 h of
incubation (p < 0.01) (Fig. 1B). The
permissive effect of glucose on insulin-induced thymidine incorporation
was time-dependent and not mimicked by either sucrose
(6-25 mM) (Fig. 1, A and B) or
fructose (data not shown). In addition, HG culturing of the cells
induced EGF-, IGF-1-, and FBS-dependent DNA synthesis 12 h earlier compared with LG (Fig. 1, A and
B).

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of glucose on
[3H]Thymidine incorporation in JAr cells.
A and B, JAr cells were cultured in medium
supplemented with LG or HG in the absence or presence of 100 nM insulin or 100 nM IGF-1 or 100 ng/ml EGF or
10% FBS for the indicated times. Alternatively, the cells were
cultured in the presence of 6 or 25 mM sucrose.
[3H]Thymidine incorporation into DNA was then determined
as described under "Experimental Procedures." For clarity, the
values measured in the absence of insulin are detailed in C. D, cells were cultured with the indicated concentrations of
glucose for 48 h and then stimulated with 100 nM
insulin followed by determination of [3H]thymidine
incorporation as above. Each value is the mean ± S.D. of
triplicate determinations in five independent experiments. Statistical
significance was assessed by unpaired Student's t test
analysis.
|
|
Glucose modulation of insulin action was dose-dependent
(Fig. 1D). A significant increase in insulin-stimulated
thymidine incorporation became detectable upon incubation of the cells
with 18 mM glucose achieving a maximum at 25 mM
glucose. As with thymidine incorporation, the insulin effect on cell
proliferation was only observed when the cells were cultured with HG
and not with LG (Fig. 2, A and
B). Also, raising glucose concentration from 6 to 25 mM decreased basal cell proliferation by 20%
(p < 0.05) (Fig. 2C). Again, no significant
difference between EGF-, IGF-1-, and FBS-induced cell proliferation was
observed at 6 and 25 mM glucose (Fig. 2, A and
B). Thus, glucose specifically enabled insulin mitogenic
effect in JAr cells and slightly reduced basal proliferation.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of glucose on JAr cell
proliferation. JAr cells were seeded at 2 × 104
cells/well in LG (A) or HG (B) medium in the
absence or the presence of 100 nM insulin or 100 nM IGF-1 or 100 ng/ml EGF or 10% FBS for the indicated
times. The cells were then trypsinized and counted with a Coulter
counter. For clarity, the values measured in the absence of insulin
either in LG or in HG medium are detailed in C. Each value
is the mean ± S.D. of triplicate determinations. Statistical
significance was assessed by t test analysis.
|
|
In different cell types, glucose affects apoptosis (35, 36). However,
no DNA laddering was observed in JAr cells cultured with LG or HG,
either in the absence or in the presence of insulin (data not shown).
Glucose Action on Insulin Mitogenic Signaling--
To explore the
mechanism of glucose action on insulin mitogenesis, we investigated
insulin binding and early signaling events in JAr cells cultured with
different glucose concentrations. Based on Western blotting with IR Ab,
IR protein content was almost identical in LG- and HG-cultured JAr
cells (Fig. 3A, top
panel). Binding levels and Kd values also did
not show significant differences in cells maintained in LG and in HG
(Table I).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of glucose on the insulin receptor
tyrosine phosphorylation and total content in JAr cells.
A, JAr cells were maintained in LG or HG medium for 48 h, stimulated with 100 nM insulin for 5 min, and
solubilized as described under "Experimental Procedures." The cell
lysates were directly blotted with insulin receptor antibodies
(IR) or phosphotyrosine antibodies (pTyr) or
partially purified by wheat germ agglutinin chromatography, followed by
IR precipitation and phosphotyrosine immunoblotting. The blotted
proteins were revealed by ECL and autoradiography. Representative
experiments are shown. Quantification of blots with wheat germ
agglutinin-purified receptors is shown in the bar graph. The
bars represent the mean values ± S.D. of four
independent experiments. B, LG or HG cells were stimulated
with 100 nM insulin or 100 nM IGF-1, lysed, and
precipitated with IGF-1 receptor Abs and blotted with phosphotyrosine
Abs. The blots were revealed by ECL and autoradiography. The
autoradiographs shown are representative of three independent
experiments. C, JAr cells were incubated with either 6 or 25 mM glucose for the indicated times. The cells were then
incubated with 125I-insulin at 4 °C for 12 h,
rinsed, and further incubated at 37 °C for 30 or 60 min as
indicated. Insulin degradation was evaluated by trichloroacetic acid
precipitation of the extracellular medium, as described under
"Experimental Procedures." The bars are the means ± S.D. of duplicate determinations in three independent experiments.
IB, immunoblot; IP, immunoprecipitation.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
125I-Insulin binding in JAr cells
Binding experiments were performed on cells kept in the presence of LG
or HG for 48, 96, and 168 h. The data represent the means ± S.D. of triplicate determinations in three independent experiments. The
Kd values were determined by Scatchard analysis of
binding data as described under "Experimental Procedures."
|
|
Upon blotting with phosphotyrosine Abs, extracts of cells cultured in 6 mM glucose showed a 95-kDa band corresponding to the IR
subunit (Fig. 3A, middle panel). The intensity of
this band increased by 35% upon exposure of the cells to insulin. Cell
culturing in the presence of 25 mM glucose decreased basal
IR tyrosine phosphorylation by 30% compared with LG cells
(p < 0.05) but resulted in a 300% increase in
insulin-dependent phosphorylation (p < 0.01). Similar changes were observed by analyzing anti-phosphotyrosine
blots of IR precipitates of partially purified receptor preparations from LG and HG cultured cells (Fig 3A, bottom
panel and bar graph). In contrast with the IR, neither
glucose nor insulin induced any change in IGF-1 receptor
phosphorylation (Fig. 3B). IGF-1 stimulated to a comparable
extent IGF-1 receptor phosphorylation in both LG- and HG-cultured
cells. In addition, culturing JAr cells in the presence of LG or HG
caused no change in their ability to degrade insulin (Fig.
3C). This finding suggested that the differences in insulin
action observed in LG and in HG were not due to changes in the ability
of the cells to degrade insulin.
To further address the molecular mechanism of glucose effect on insulin
action, we next investigated phosphorylation of IRS1 in the JAr cells.
As shown in Fig. 4A,
insulin-independent IRS1 phosphorylation was 50% lower in HG-treated
cells as compared with LG-treated cells (p < 0.05).
However, insulin increased IRS1 phosphorylation by 400% of control in
HG-cultured cells (p < 0.01) but elicited no
significant effect in LG cells. The differences in IRS1 phosphorylation
in cells cultured in LG and HG were accompanied by similarly sized
differences in MAPK phosphorylation (Fig. 4B). There were no
changes in the IRS1 and MAPK protein levels in LG and HG cells (Fig
4C).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of glucose on IRS1 and MAPK
phosphorylations. JAr cells were incubated in LG or HG medium in
the absence or the presence of 100 nM insulin as outlined
in the legend to Fig. 4. The cell lysates were either
immunoprecipitated with IRS1 and then immunoblotted with
phosphotyrosine Ab (A) or immunoblotted with
phospho-p44/42 MAPK Ab (B). Detection was achieved by
ECL and autoradiography. The bars represent the means ± S.D. of values from four (IRS1) and five (P-MAPK) independent
experiments. Representative autoradiographs are shown in the
insets. For control, filters were blotted again with IRS1
and MAPK antibodies (C).
|
|
Effect of Glucose on Protein-Tyrosine Phosphatase Activity--
We
next investigated whether the glucose effect on IR and IRS1
phosphorylation is mediated by changes in cellular PTPase activity. As
shown in Table II, exposure to HG
increased PTPase activity in JAr cell extracts by almost 300%
(p < 0.01). Insulin inhibited PTPase activity in LG
cells by about 30% (not statistically significant) and almost
completely abolished the effect of HG (p < 0.05).
PTPase activity was also measured in IR and IRS1 immunoprecipitates
from the cells. Neither glucose nor insulin affected the
IR-co-precipitated PTPase, however. IN contrast, IRS1-associated PTPase
activity was 350% higher in HG than in LG cells (p < 0.01) and was blocked by insulin stimulation.
View this table:
[in this window]
[in a new window]
|
Table II
Tyrosine phosphatase (PTPase) activity in JAr cells
PTPase activity was measured from total cell lysates (50 µg of
protein) and from IR and IRS1 precipitates (500 µg of proteins, as
determined before the immunoprecipitation) using
p-nitrophenylphosphate as substrate. The activity is
expressed as nmol mg 1 h 1 as described under
"Experimental Procedures." The data are the means ± S.D. of
three independent experiments.
|
|
To verify whether specific PTPase(s) are involved in glucose regulation
of IR signaling, we evaluated the expression of SHP-2, PTP1B, and LAR
in JAr cells. All of these PTPases are involved in insulin signaling
(37-39), and as shown in Fig.
5A, all are expressed in the
JAr cells. Neither glucose nor insulin caused any change in the
expression levels of these PTPases. Interestingly, in HG-cultured cell
extracts but not in those from LG cells, SHP-2 co-precipitated with
IRS1 (Fig. 5B). Further exposure of HG-treated cells to
insulin completely abolished IRS1-SHP-2 co-precipitation. No IR-SHP-2
co-precipitation was detected either in HG or in LG cells. LAR and
PTP1B association with IRS1 was barely detectable in JAr cells and was
not modified by glucose or insulin treatment (Fig. 5C). As
shown in Fig. 6B, phosphatase
activity in SHP-2 immunoprecipitates was increased by 400% upon
exposure of the cells to HG. Same as in the IRS1 precipitates, insulin
stimulation of the cells completely inhibited PTPase activity in the
SHP-2 precipitates.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Glucose effect on SHP-2, LAR, and PTP1B
protein expression and IRS1 association in JAr cells. JAr cells
were incubated in LG or HG medium in the absence or the presence of 100 nM insulin as indicated. The cells were solubilized, and
the cell lysates were blotted with SHP-2, LAR, and PTP1B antibodies
(A). Alternatively, the lysates were immunoprecipitated with
IRS1 or IR antibodies followed by blotting with SHP-2 (B) or
LAR or PTP1B antibodies (C). The blots were revealed by ECL
and autoradiography. The autoradiographs shown are representative of
three (A), four (B), and two (C)
experiments. IB, immunoblot; IP,
immunoprecipitation.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
Antisense inhibition of SHP-2 in JAr
cells. JAr cells were transiently transfected with SHP-2 sense
(S) or antisense (AS) oligonucleotides. The cells
were solubilized, immunoprecipitated with SHP-2 antibodies, and further
blotted with SHP-2 antibodies (A). The filters were revealed
by ECL and autoradiography. The autoradiograph shown is representative
of three independent experiments. Alternatively, the cell lysates were
precipitated with SHP-2 antibodies, and SHP-2 activity was measured in
the precipitates as described under "Experimental Procedures." The
bars represent the mean values ± S.D. of four
independent experiments. C stands for untransfected cells.
IB, immunoblot; IP, immunoprecipitation.
|
|
To prove SHP-2 involvement in glucose action on insulin mitogenesis, we
have transiently transfected SHP-2 antisense oligonucleotides (SHP-2-AS) in the JAr cells. As shown in Fig. 6A, the
antisense reduced SHP-2 expression by >70% (p < 0.001). Consistently, SHP-2 activity was barely detectable in SHP-2
precipitates from cells transfected with SHP-2-AS but unmodified by
control oligonucleotides (Fig. 6A). Also, the SHP-2-AS
completely inhibited SHP-2-IRS1 co-precipitation in extracts from
HG-treated cells (Fig. 7A,
top panel). In HG-cultured cells, a block of SHP-2
expression increased insulin-independent IR and IRS1 phosphorylation,
respectively, by 30 and 50% (p < 0.01). The effect of
the antisense was accompanied by a 300% decrease in insulin-stimulated
phosphorylation of IR and IRS1. SHP-2-AS treatment of HG cells also
returned basal and insulin-stimulated thymidine incorporation to levels
comparable with those observed in LG cells (Fig. 7B).
SHP-2-AS had no effect on basal and insulin-dependent IR
and IRS1 phosphorylation (Fig. 7A, middle and
bottom panel, lanes E and F
versus lanes A and B) as well as
thymidine incorporation (Fig. 7B) in LG-exposed cells.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of SHP-2 antisense on IRS1-SHP-2
association, IRS1 and IR phosphorylation, and
[3H]thymidine incorporation in JAr cells.
A, JAr cells were transiently transfected with SHP-2 sense
(S) or antisense (AS) oligonucleotides and then
stimulated with 100 nM insulin. The cell lysates were
immunoprecipitated with IRS1 or IR antibodies followed by blotting with
SHP-2 or phosphotyrosine (pTyr) antibodies, as indicated.
The blots were revealed by ECL and autoradiography. The autoradiographs
shown are representative of three independent experiments.
B, alternatively, oligonucleotide transfected and
untransfected cells (C) were stimulated with insulin and
assayed for [3H]thymidine incorporation as described
under "Experimental Procedures." The bars represent the
means ± S.D. of triplicate determinations in five independent
experiments. IB, immunoblot; IP,
immunoprecipitation.
|
|
To address the tissue specificity of glucose action on SHP-2 activity
and insulin signaling, we have further compared SHP-2 activity in the
choriocarcinoma BeWo cells and in 3T3 fibroblasts. As shown in Fig.
8, HG exposure of BeWo cells increased
SHP-2 activity, as in JAr cells. Also, in the BeWo cells, as well as in
the JAr cells, insulin blocked glucose activation of SHP-2. By contrast
SHP-2 activity was identical in 3T3 cells whether cultured in HG or in
LG and increased upon insulin exposure by 500% of control both upon LG
and HG treatment. In addition, in LG-cultured BeWo cells, insulin
failed to increase DNA synthesis. HG culturing determined a 20%
reduction of thymidine incorporation compared with LG but allowed
a > 300% increase in DNA synthesis. By contrast, insulin induced
similar increases in thymidine incorporation in 3T3 cells both in the
presence of LG and of HG, and basal levels of thymidine incorporation
were not modified by glucose in these cells.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 8.
Glucose and insulin action on SHP-2 activity
and thymidine incorporation in BeWo and 3T3 cells. BeWo and 3T3
cells were cultured in either LG or HG medium. The cells were then
stimulated with insulin for 10 min, and SHP-2 activity was assayed as
described under "Experimental Procedures" (A).
Alternatively, the cells were incubated with 100 nM insulin
and then assayed for thymidine incorporation as outlined in the legend
to Fig. 8 (B). The bars represent the means ± S.D. of
duplicate determinations in three (A) and four
(B) independent experiments.
|
|
Glucose Effect on SHP-2 Intracellular Localization--
To further
investigate the mechanism of SHP-2 activation by glucose, we compared
the intracellular localization of SHP-2 and IRS1 in JAr cells. To this
end, we prepared internal membrane (IM) and cytosolic fractions from
JAr cells. The purity of the different fractions is shown in Table
III. As shown in Fig.
9A, in LG-cultured cells,
SHP-2 was largely cytosolic either in the absence or in the presence of
insulin. In contrast, HG culturing led to a prominent SHP-2
localization in the IM compartment of the cells. Insulin exposure of
HG-cultured cells determined translocation of SHP-2 back to the
cytosol, however. Different from SHP-2, IRS1 was equally distributed in
the cytosol and IM fractions of HG- and LG-treated cells. Upon insulin
exposure, however, about 80% of IRS1 translocated from the cytosol to
the IM fraction both in LG and in HG cells. Based on
anti-phosphotyrosine blotting, phosphorylated IRS1 predominantly
localized (> 85%) in the IM fraction (Fig. 9C). Identical
results were also obtained in the BeWo cells (data not shown).
View this table:
[in this window]
[in a new window]
|
Table III
JAr cell subfractionation
JAr cells were homogenized, and IM, cytosolic (CY), and plasma membrane
(PM) fractions were obtained as described under "Experimental
Procedures." The purity of the different fractions was assessed by
Western blotting equal amounts of proteins with cytochrome c
oxidase or tubulin antibodies or by comparison of 5'-nucleotidase
activity. The results are reported as percentages ± S.D. of the
total levels/activity measured in the homogenate. ND stands for not
detectable. The figures in this legend did not show significant
difference whether the cells are cultured in LG or HG media.
|
|

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 9.
Glucose action on SHP-2 and IRS1 subcellular
localization in JAr cells. JAr cells were cultured in HG or LG
medium and stimulated with 100 nM insulin for 10 min. The
cells were rinsed and homogenized, and IM and cytosol (Cy)
fractions prepared as described under "Experimental Procedures."
Equal amount of proteins from these fractions and the total homogenate
(T) were then immunoblotted with IRS1 or SHP-2 antibodies
(A). Aliquots of the IRS1 precipitates were also blotted
with phosphotyrosine antibodies (B). The autoradiographs
shown are representative of four independent experiments.
IB, immunoblot; IP, immunoprecipitation.
|
|
Thus, in JAr and BeWo cells glucose induces translocation of SHP-2 to
the IM of the cells where most tyrosine-phosphorylated IRS1
localizes. Insulin stimulation of the cells simultaneously relocalizes
SHP-2 to the cytosol and promotes IRS1 phosphorylation.
 |
DISCUSSION |
We have investigated glucose regulation of cell growth in the JAr
human choriocarcinoma cell line. These cells maintain in culture many
features characteristic of human first trimester trophoblast, including
chorionic gonadotropin and progesterone secretion (21). Because of
these features, JAr cells have been widely used to investigate glucose
and insulin action in placenta (19, 20). We found that insulin does not
induce proliferation of JAr cells when they are maintained in low
glucose medium. This finding is consistent with previous reports
showing that in vivo insulin is a weak mitogenic factor in
placenta when glycemic control is achieved (17, 40). As recently
reported by Weiss et al. (19), chronic exposure
of JAr cells to high glucose concentrations slightly inhibited
proliferation. In addition, we now show that high glucose induces
insulin proliferative effect in JAr cells. The effect of glucose on
insulin-induced mitogenesis was dose-dependent and specific
for insulin because IGF-1, EGF, and serum stimulated cell proliferation
to the same extent both at low and at high glucose concentrations.
Glucose permissive action on insulin mitogenic effect also occurred in
the BeWo choriocarcinoma cell line, suggesting that high glucose
concentrations might contribute to placenta hypercellularity in
vivo as well.
Glucose cooperation with growth factor signaling has already been
described in different cell types (5, 41). For instance, in insulinoma
cells, glucose induces a dose-dependent increase of nerve
growth factor effect on insulin secretion, but the mechanisms remain
elusive (5, 41). However, the data in the present report show for the
first time that extracellular glucose also controls insulin mitogenic
action. Our study shows that glucose does not affect IR number or
affinity in the JAr cells. Still, chronic exposure to high glucose
concentrations slightly reduced the basal activation state of the
IRS1/MAPK cascade but significantly increased insulin-stimulated
signaling along this pathway. Thus, at least in part, glucose
potentiates insulin mitogenic signaling in JAr cells by inducing the
IRS1/MAPK pathway. We envisioned two possible mechanisms for this
glucose regulatory effect. Firstly, in JAr cells, glucose may affect
PKC activity. These Ser/Thr kinases phosphorylate several insulin
signaling molecules and inhibit their subsequent tyrosine
phosphorylation and function (42, 43). Hence, our previous work in
muscle cells showed that glucose rapidly causes reverse translocation
of PKC
from the plasma membrane to the cytoplasm. Reverse
translocation of PKC
reduces PKC
-IR association and IR Ser/Thr
phosphorylation and acutely activates the insulin signaling system in
these cells (42). A similar mechanism is unlikely to account for
glucose effect on insulin mitogenic signaling in the JAr cells,
however. In fact, treatment of JAr cells with the PKC inhibitor
bisindolylmaleimide does not affect IR and IRS1 phosphorylation in the
presence of either low or high glucose concentrations (data not shown).
Alternatively, in the JAr cells, glucose may regulate the action of
PTPases on key elements of the insulin signaling pathway (37, 44).
Consistent with this hypothesis, we show here that the activity of the
SHP-2 PTPase is increased in extracts of JAr as well as in those from BeWo placenta cells cultured in high glucose medium. In addition, we
have shown that SHP-2 but not PTP1B or LAR co-precipitated with IRS1 in
JAr cell extracts. SHP-2-IRS1 association only occurred in HG cultured
cells. Importantly, antisense block of SHP-2 expression in HG cells
returned IRS1 phosphorylation and insulin mitogenesis to levels
comparable with those of cells maintained in low glucose medium,
indicating that SHP-2 mediates the permissive effect of glucose on
insulin signaling through the IRS1/MAPK pathway.
Acute stimulation of HG-cultured cells with insulin prevented
SHP-2-IRS1 co-precipitation. Thus, in JAr cells, insulin causes the
release of the SHP-2-IRS1 association induced by the chronic exposure
to HG levels. We propose that the SHP-2 association is responsible for
the reduced IRS1 phosphorylation levels we have observed in HG-cultured
JAr cells. Subsequent exposure of these cells to insulin releases the
association and enables IRS1 to undergo tyrosine phosphorylation more
effectively than in LG cells, which feature higher basal levels of IRS1
phosphorylation. Enhanced phosphorylation of IR/IRS1 in HG-cultured
cells, in turn, more actively conveys insulin signal through the
MAPK/mitogenic pathway. Thus, by fostering SHP-2 association, glucose
maintains IRS1 in a low phosphorylation state. Insulin then releases
the association, enabling IRS1 to achieve higher levels of
phosphorylation by IR kinase. The changes in IRS1 phosphorylation
determined by HG exposure were paralleled by similar changes in the
phosphorylation of IR kinase. In contrast with IRS1, however, no
glucose- and insulin-dependent IR-SHP-2 co-precipitation
was detectable in the JAr cells. SHP-2 association with the IR may be
weaker than with IRS1, preventing co-immunoprecipitation. In addition,
previous work by Solow et al. (45) evidenced that IRS1 may
determine the activation state of the IR through a
PTPase-dependent mechanism. Thus, HG effects on IR tyrosine
phosphorylation may also reflect the regulation of IRS1 activity by
SHP-2.
SHP-2 is a cytosolic PTPase (46). However, in the present report, we
show that exposure of JAr cells to high glucose concentrations determines SHP-2 translocation from the cytosol to the internal membrane compartment. This compartment also hosts most of the tyrosine-phosphorylated IRS1 present in the insulin-unstimulated cells,
so that the SH2 domain of SHP-2 may bind IRS1 phosphotyrosine. Subsequent stimulation of the cells by insulin reverted SHP-2 translocation and relocalized most cellular SHP-2 in the cytosolic fraction. Thus, chronic exposure of JAr cells to high glucose levels
fosters SHP-2-IRS1 co-localization. Insulin relocalizes SHP-2 in a
compartment of the cells distinct from the one that hosts
tyrosine-phosphorylated IRS1 and prevents SHP-2-IRS1 association. The
sequence(s) of SHP-2 necessary for glucose and insulin control of SHP-2
localization are currently under investigation in our laboratory.
Previous studies evidenced that SHP-2 plays an important role in
transducing insulin mitogenic signals (37, 47). Consistent with these
reports, we propose that antisense inhibition of SHP-2 expression in
JAr cells led to a significant inhibition of insulin-induced DNA
synthesis. Interestingly, however, we have also found that HG exposure
slightly inhibits DNA synthesis but increases SHP-2 activity. Thus, in
JAr cells, SHP-2 activation may not be sufficient to elicit growth
stimulatory responses. Hence, when the cells are stimulated with
insulin in the presence of high glucose levels, coincidence of
SHP-2-IRS1 dissociation and induction of MAPK and DNA synthesis
suggests that SHP-2 might play a regulatory rather than a direct causal
role in JAr cell proliferation by controlling the phosphorylation state
of signaling molecules. In 3T3 cells, the expression of a catalytically
inactive SHP-2 causes a reduction in MAPK phosphorylation and insulin
mitogenesis with no effect on IR and IRS1 phosphorylation (47). In
contrast, in JAr cells SHP-2 modulates the insulin mitogenic signaling
cascade by acting at the level of IR and IRS1 phosphorylation. It
appears therefore that the function of SHP-2, as well as that of
glucose, features tissue specificity. Regulation of SHP-2 also appears
to involve different mechanisms in different cell types. In fact,
previous evidence indicates that insulin stimulates SHP-2 activity in
fibroblasts (47). Here, we show that both the JAr and BeWo placenta
cells feature glucose but not insulin activation of SHP-2. Glucose
itself impinges on molecular mechanisms in a tissue-specific fashion. For example, it stimulates MAPK activation in INS-1 cells (5, 41) and
activates PKC in many other cell types (4, 42, 43).
In conclusion, in the present report, we have shown that glucose exerts
a permissive action on insulin mitogenesis in placenta cells.
Glucose-induced activation and intracellular delocalization of SHP-2 is
a key mechanism controlling insulin signal transduction through the
IRS1/MAPK pathway.
 |
ACKNOWLEDGEMENT |
We are grateful to Dr. C. Miele for the
continuous support and advice during the course of this work.
 |
FOOTNOTES |
*
This work was supported in part by European Community Grant
QLRT-1999-00674 (to F. B.), grants from the Associazione Italiana per la Ricerca sul Cancro (to F. B. and P. F.), the Ministero dell'Università e della Ricerca Scientifica and the
Consiglio Nazionale delle Ricerche (C. N. R.). Target Project on
Biotechnology (to F. B.), Telethon-Italy Grant 0896 (to F. B.), and Novartis Pharmaceuticals.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Via Pansini 5-80131
Napoli, Italy. Tel.: 39-81-7462979; Fax: 39-81-7463865; E-mail: giuseppebifulco@hotmail.com.
Published, JBC Papers in Press, April 30, 2002, DOI 10.1074/jbc.M202962200
 |
ABBREVIATIONS |
The abbreviations used are:
EGF, epidermal
growth factor;
IGF-1, insulin-like growth factor 1;
IRS, insulin
receptor substrate;
MAPK, mitogen-activated protein kinase;
DMEM, Dulbecco's modified Eagle's medium;
FBS, fetal bovine serum;
LG, low
concentration (6 mM) glucose;
HG, high concentration (25 mM) glucose;
IR, insulin receptor, IRS1, insulin receptor
substrate 1;
PTPase, protein-tyrosine phosphatase;
Ab, antibody;
SHP-2-AS, SHP-2 antisense oligonucleotides;
IM, internal membrane;
PKC, protein kinase C.
 |
REFERENCES |
| 1.
|
Shim, H.,
Chun, Y. S.,
Lewis, B. C.,
and Dang, C. V.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
1511-1516[Abstract/Free Full Text]
|
| 2.
|
Fine, E. L.,
Horal, M.,
Chang, T. I.,
Fortin, G.,
and Loeken, M. R.
(1999)
Diabetes
48,
2454-2462[Abstract]
|
| 3.
|
Kikkawa, R.,
Haneda, M.,
Togawa, M.,
Koya, D.,
Kajiwara, N.,
and Shigeta, Y.
(1993)
Diabetologia
36,
276-281[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sjoholm, A.
(1997)
Diabetes
46,
1141-1147[Abstract]
|
| 5.
|
Frodin, M.,
Sekine, N.,
Roche, E.,
Filloux, C.,
Prentki, M.,
Wollheim, C. B.,
and Van Obberghen, E.
(1995)
J. Biol. Chem.
270,
7882-7889[Abstract/Free Full Text]
|
| 6.
|
Ho, F. M.,
Liu, S. H.,
Liau, C. S.,
Huang, P. J.,
and Lin-Shiau, S. Y.
(2000)
Circulation
101,
2618-2624[Abstract/Free Full Text]
|
| 7.
|
Nelson, B. A.,
Robinson, K. A.,
and Buse, M. G.
(2000)
Diabetes
49,
981-991[Abstract]
|
| 8.
|
Zhang, Q.,
Berggren, P. O.,
and Tally, M.
(1997)
J. Biol. Chem.
272,
23703-23706[Abstract/Free Full Text]
|
| 9.
|
Kanety, H.,
Moshe, S.,
Shafrir, E.,
Lunenfeld, B.,
and Karasik, A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1853-1857[Abstract/Free Full Text]
|
| 10.
|
Pinter, E.,
Haigh, J.,
Nagy, A.,
and Madri, J. A.
(2001)
Am. J. Pathol.
158,
1199-1206[Abstract/Free Full Text]
|
| 11.
|
Crossey, P. A.,
Jones, J. S.,
and Leill, J. P.
(2000)
Diabetes
49,
457-465[Abstract]
|
| 12.
|
Federici, M.,
Giaccari, A.,
Hribal, M. L.,
Giovannone, B.,
Lauro, D.,
Morviducci, L.,
Pastore, L.,
Tamburano, G.,
Lauro, R.,
and Sesti, G.
(1999)
Diabetes
48,
2277-2285[Abstract]
|
| 13.
|
Giorgino, F.,
Chen, J. H.,
and Smith, R. J.
(1992)
Endocrinology
130,
1433-1444[Abstract]
|
| 14.
|
The Diabetes Control and Complications Trial Research Group.
(1993)
N. Engl. J. Med.
329,
977-986[Abstract/Free Full Text]
|
| 15.
|
Lao, T. T.,
Lee, C. P.,
and Wong, W. M.
(1997)
Placenta
18,
227-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Chen, C. F.,
Kurachi, H.,
and Fujida, Y.
(1988)
J. Clin. Endocrinol. Metab.
71,
923-928[Abstract]
|
| 17.
|
Li, R. H.,
and Zhuang, L. Z.
(1997)
Hum. Reprod.
4,
830-834
|
| 18.
|
Han, V. K.,
Hunter, E. S.,
and Pratt, R. M.
(1987)
Mol. Cell. Biol.
7,
2335-2343[Abstract/Free Full Text]
|
| 19.
|
Weiss, U.,
Cervar, M.,
Puerstner, P.,
Schmut, O.,
Haas, J.,
Mauschitz, R.,
Arikan, G.,
and Desoye, G.
(2000)
Diabetologia
44,
209-219
|
| 20.
|
Boileau, P.,
Cauzac, M.,
Pereira, M. A.,
Girard, J.,
and Hauguel de Mouzon, S.
(2001)
Endocrinology
142,
3974-3979[Abstract/Free Full Text]
|
| 21.
|
Bahn, R. S.,
Speeg, K. V.,
Ascoli, M.,
and Rabin, D.
(1980)
Endocrinology
107,
2121-2123[Abstract]
|
| 22.
|
Kroder, G.,
Bossenmaier, B.,
Kellerer, M.,
Capp, E.,
Stoyanov, B.,
Muhlhofer, A.,
Berti, L.,
Horikoshi, H.,
Ullrich, A.,
and Haring, H.
(1996)
J. Clin. Invest.
97,
1471-1477[Medline]
[Order article via Infotrieve]
|
| 23.
|
Pazdrak, K.,
Adachi, T.,
and Alam, R.
(1997)
J. Exp. Med.
186,
561-568[Abstract/Free Full Text]
|
| 24.
|
Simpson, I. A.,
Yver, D. R.,
Hissin, P. J.,
Wardzala, L. J.,
Karnieli, E.,
Salans, L. B.,
and Cushman, S. W.
(1983)
Biochim. Biophys. Acta
19,
393-407
|
| 25.
|
Yang, T. J.,
Krausz, K. W.,
Shou, M.,
Yang, S. K.,
Buters, J. T.,
Gonzales, F. J.,
and Gelboin, H. V.
(1998)
Biochem. Pharmacol.
55,
1633-1640[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Hsu, L. C.,
and White, R. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12983-12988[Abstract/Free Full Text]
|
| 27.
|
Ipata, P. L.
(1967)
Anal. Biochem.
20,
30-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Donath, M. Y.,
Gross, D. J.,
Cerasi, E.,
and Kaiser, N.
(1999)
Diabetes
48,
738-744[Abstract]
|
| 29.
|
Beguinot, F.,
Kahn, C. R.,
Moses, A. C.,
and Smith, R. J.
(1986)
Endocrinology
118,
446-455[Abstract]
|
| 30.
|
Formisano, P.,
Sohn, K. J.,
Miele, C., Di,
Finizio, B.,
Petruzziello, A.,
Riccardi, G.,
Beguinot, L.,
and Beguinot, F.
(1993)
J. Biol. Chem.
268,
5241-5248[Abstract/Free Full Text]
|
| 31.
|
Formisano, P., De,
Novellis, G.,
Miele, C.,
Tripodi, F.,
Caruso, M.,
Palombo, G.,
Beguinot, L.,
and Beguinot, F.
(1994)
J. Biol. Chem.
269,
16242-16246[Abstract/Free Full Text]
|
| 32.
|
Miele, C.,
Caruso, M.,
Calleja, V.,
Auricchio, R.,
Oriente, F.,
Formisano, P.,
Condorelli, G.,
Cafieri, A.,
Sawka-Verhelle, D.,
Van Obberghen, E.,
and Beguinot, F.
(1999)
J. Biol. Chem.
274,
3094-3102[Abstract/Free Full Text]
|
| 33.
|
Marshall, C. J.
(1995)
Cell
80,
225-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Okada, Y.,
Yoshida, M.,
Baba, S.,
and Shii, K.
(1998)
Diabetes Res. Clin. Pract.
41,
157-163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Hall, J. L.,
Matter, C. M.,
Wang, X.,
and Gibbons, G. H.
(2000)
Circ. Res.
87,
574-580[Abstract/Free Full Text]
|
| 36.
|
Federici, M.,
Hribal, M.,
Perego, L.,
Ranalli, M.,
Caradonna, Z.,
Perego, C.,
Usellini, L.,
Nano, R.,
Bonini, P.,
Bertuzzi, F.,
Marlier, L. N.,
Davalli, A. M.,
Carandente, O.,
Pontiroli, A. E.,
Melino, G.,
Marchetti, P.,
Lauro, R.,
Sesti, G.,
and Folli, F.
(2001)
Diabetes
50,
1290-1301[Abstract/Free Full Text]
|
| 37.
|
Khune, M. R.,
Pawson, T.,
Lienhard, G. E.,
and Feng, G. S.
(1993)
J. Biol. Chem.
268,
11479-11481[Abstract/Free Full Text]
|
| 38.
|
Goldstein, B. J.,
Bittner Kowalczyk, A.,
White, M. F.,
and Harbeck, M.
(2000)
J. Biol. Chem.
275,
4283-4289[Abstract/Free Full Text]
|
| 39.
|
Tsujikawa, K.,
Kawakami, N.,
Uchino, Y.,
Ichijo, T.,
Furukawa, T.,
Saito, H.,
and Yamamoto, H.
(2001)
Mol. Endocrinol.
15,
271-280[Abstract/Free Full Text]
|
| 40.
|
Simpson, E. R.,
and MacDonald, P. C.
(1981)
Annu. Rev. Physiol.
43,
163-188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Khoo, S.,
and Cobb, M. H.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5599-5604[Abstract/Free Full Text]
|
| 42.
|
Caruso, M.,
Miele, C.,
Oriente, F.,
Maitan, A.,
Bifulco, G.,
Andreozzi, F.,
Condorelli, G.,
Formisano, P.,
and Beguinot, F.
(1999)
J. Biol. Chem.
274,
28637-28644[Abstract/Free Full Text]
|
| 43.
|
Galante, P.,
Mosthaf, L.,
Kellerer, M.,
Berti, L.,
Tippmer, S.,
Bossenmaier, B.,
Fujiwara, T.,
Okuno, A.,
Horikoshi, H.,
and Haring, H. U.
(1995)
Diabetes
44,
646-651[Abstract]
|
| 44.
|
Kulas, D. T.,
Zhang, W. R.,
Goldstein, B. J.,
Furlanetto, R. W.,
and Mooney, R. A.
(1995)
J. Biol. Chem.
270,
2435-2438[Abstract/Free Full Text]
|
| 45.
|
Solow, B. T.,
Harada, S.,
Goldstein, B. J.,
Smith, J. A.,
White, M. F.,
and Jarett, L.
(1999)
Mol. Endocr.
1,
1784-1798
|
| 46.
|
Calera, M. R.,
Vallega, G.,
and Pilch, P. F.
(2000)
J. Biol. Chem.
275,
6308-6312[Abstract/Free Full Text]
|
| 47.
|
Milarski, K. L.,
and Saltiel, A. L.
(1994)
J. Biol. Chem.
269,
21239-21243[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. C. Choi, R. Holtz, M. G. Petroff, N. Alfaidy, and S. P. Murphy
Dampening of IFN-{gamma}-Inducible Gene Expression in Human Choriocarcinoma Cells Is Due to Phosphatase-Mediated Inhibition of the JAK/STAT-1 Pathway
J. Immunol.,
February 1, 2007;
178(3):
1598 - 1607.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Oriente, F. Andreozzi, C. Romano, G. Perruolo, A. Perfetti, F. Fiory, C. Miele, F. Beguinot, and P. Formisano
Protein Kinase C-{alpha} Regulates Insulin Action and Degradation by Interacting with Insulin Receptor Substrate-1 and 14-3-3{epsilon}
J. Biol. Chem.,
December 9, 2005;
280(49):
40642 - 40649.
[Abstract]
[Full Text]
[PDF]
|
 |
|